Melanoma/Skin Cancer News

An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune checkpoint inhibitors.

More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.

Superficial curettage plus imiquimod cream 5% in the treatment of nodular basal cell carcinoma showed more treatment failure at 5 years vs. surgical excision, according to a study.

Offering image-guided superficial radiation therapy to rural populations could mend health disparities in nonmelanoma skin cancer treatment, according to a study published in Cancers.

Individuals with vitiligo did not display a significantly increased risk for cancer compared with the general population, according to a study.

Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.

Healio will present its fourth annual Disruptive Innovators Awards for oncology/hematology this spring.

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, according to the agent’s manufacturer.

A phase 3 study of Ameluz and RhodoLED photodynamic therapy for superficial basal cell carcinoma has reached a key milestone as the final patient has completed the 1-year follow-up visit, Biofrontera announced in a press release.